Faricimab

Item number	Size	Datasheet	Manual	SDS	Delivery time	Price
TGM-T78253-1mg	1 mg				5 - 10 business days*	610.00€
TGM-T78253-5mg	5 mg				5 - 10 business days*	1,602.00€
TGM-T78253-10mg	10 mg	-	-	-	5 - 10 business days*	2,541.00€
TGM-T78253-25mg	25 mg	-	-	-	5 - 10 business days*	3,785.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A.... more

Close menu

Product information "Faricimab"

Description: Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO. Target: RAAS, VEGFR. References: Canonica J, et al. Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J]. Front Cell Neurosci. 2023 Jun 12,17:1192464.

Keywords:	RG-7716 , RG7716
Supplier:	TargetMol
Supplier-Nr:	T78253

Properties

Application:	Targets angiopoietin 2 (ANGPT2)
Conjugate:	No
Format:	32160702

Database Information

CAS :	1607793-29-2\| Matching products
KEGG ID :	K05448 \| Matching products

Handling & Safety

Storage:	-20°C
Shipping:	+4°C (International: +4°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

Information about the product reference will follow. more

Close menu

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "Faricimab"

Write a review